

OPEN

Genetic polymorphisms of *IL17A* associated with Chagas disease: results from a meta-analysis in Latin American populations

Mariana Strauss^{1*}, Miriam Palma-Vega², Desiré Casares-Marfil², Pau Bosch-Nicolau³, María Silvana Lo Presti¹, Israel Molina³, Clara Isabel González⁴, Chagas Genetics CYTED Network[†], Javier Martín^{2*} & Marialbert Acosta-Herrera^{2*}

Genetic factors and the immunologic response have been suggested to determine the susceptibility against the infection and the outcome of Chagas disease. In the present study, we analysed three *IL17A* genetic variants (rs4711998, rs8193036 and rs2275913) regarding the predisposition to *Trypanosoma cruzi* infection and the development of chronic Chagas cardiomyopathy (CCC) in different Latin American populations. A total of 2,967 individuals from Colombia, Argentina, Bolivia and Brazil, were included in this study. The individuals were classified as seronegative and seropositive for *T. cruzi* antigens, and this last group were divided into asymptomatic and CCC. For *T. cruzi* infection susceptibility, the *IL17A* rs2275913*A showed a significant association in a fixed-effect meta-analysis after a Bonferroni correction ($P = 0.016$, OR = 1.21, 95%CI = 1.06–1.41). No evidence of association was detected when comparing CCC vs. asymptomatic patients. However, when CCC were compared with seronegative individuals, it showed a nominal association in the meta-analysis ($P = 0.040$, OR = 1.20, 95%CI = 1.01–1.45). For the *IL17A* rs4711998 and rs8193036, no association was observed. In conclusion, our results suggest that *IL17A* rs2275913 plays an important role in the susceptibility to *T. cruzi* infection and could also be implicated in the development of chronic cardiomyopathy in the studied Latin American population.

Chagas disease caused by the protozoan *Trypanosoma cruzi* is a parasitic infection endemic in Latin American countries, which is nowadays increasingly becoming a global health problem, due to migration to non-endemic areas^{1,2}. Around 6 to 7 million people are estimated to be infected worldwide, mostly in Latin America^{1,3}. During the acute phase of the disease, the increase of parasitic load induces an inflammatory process for the control of the pathogen⁴. Ten to thirty years after infection, around 30 to 40% of chronically infected patients can develop cardiomyopathy or/and megaviscera. The symptoms include cardiac conduction abnormalities, myocardial contractile dysfunction, arrhythmias, dysphagia, regurgitation, and severe constipation, among others. The cardiac involvement is the most frequent manifestation of the disease^{5,6}. The characteristics of this phase vary in different patients and in different regions of the endemic area⁷.

After the infection with *T. cruzi*, interleukin-17A (IL-17A) is produced by T helper 17 (Th17) cells, subset of CD4+ T cells, and innate lymphoid cells^{8,9}. More recently, it has been described that B cells are also an important source of IL-17A and IL-17F, produced as well after *T. cruzi* infection^{10,11}. In response to the infection, IL-17-A, induces a rapid proinflammatory cascade of chemokines and cytokines that facilitates the recruitment and activation of neutrophils and monocytes required for the early control of the pathogen by the immune system^{12,13}. In the chronic phase of the disease, several studies suggest that the clinical progression of Chagas cardiomyopathy involves the overexpression of IL-17 by Th17 cells and B cells^{14,15}.

¹Centro de Estudios e Investigación de la Enfermedad de Chagas y Leishmaniasis, FCM, INICSA-CONICET-UNC, Córdoba, Argentina. ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, España. ³Unidad de Medicina Tropical y Salud Internacional Hospital Universitario Vall d'Hebron, PROSICS, Barcelona, España. ⁴GIEM, Universidad Industrial de Santander, Bucaramanga, Colombia. [†]A comprehensive list of consortium members appears at the end of the paper. *email: marianastr86@gmail.com; javiermartin@ipb.csic.es; m.acostaherrera@ipb.csic.es

	Seropositive		Seronegative	Total
	CCC	ASY		
Sex (% males)	40%*	31%*	36%**	
Median age, yr (P25–P75)	60 (51–68)*	48 (41–57)*	46 (31–62)**	
Colombian	576	361	640	1,577
Argentinian	182	90	78	350
Bolivian	100	530	—	630
Brazilian ²⁸	212	48	150	410
Total	1,070	1,029	868	2,967

Table 1. Demographic characteristics of patients included in the present study classified by Chagas disease serology and symptoms. CCC: chronic Chagas cardiomyopathy. ASY: asymptomatic. *Data from the Colombian, Argentinian and Bolivian cohorts. **Data from the Colombian and Argentinian cohorts.

SNP	Colombian cohort		Argentinian cohort		Brazilian cohort		Meta-analysis	
	OR (L95–U95)	P	OR (L95–U95)	P	OR (L95–U95)	P	OR (L95–U95)	P
rs4711998*A	0.94 (0.78–1.14)	0.528	1.38 (0.90–2.12)	0.143	—	—	0.99 (0.84–1.17)	0.946
rs8193036*C	0.83 (0.70–0.99)	0.043	1.34 (0.89–20.2)	0.164	—	—	0.89 (0.76–1.05)	0.169
rs2275913*A	1.16 (0.95–1.4)	0.136	1.07 (0.67–1.69)	0.793	1.46 (1.05–2.05)	0.032	1.21 (1.06–1.41)	0.016

Table 2. Meta-analysis of *IL17A* variants, Latin American cohorts for *T. cruzi* infection susceptibility (seropositive vs. seronegative individuals). Total number of individuals: rs4711998 and rs8193036: seropositive, n = 1209 and seronegative, n = 718; rs2275913: seropositive, n = 1469 and seronegative, n = 868. OR: odds ratios, L95–U95: confidence intervals of 95% L: lower limit; U: upper limit. Significant P value is shown in bold. Significant association based on the Bonferroni correction $P < 0.017$.

It's well known that, genetic factors and immunologic response may determine the susceptibility against the infection and the outcome of Chagas disease^{16–19}. Thus, polymorphisms in genes encoding cytokines may influence the level of cytokines production and, consequently, cause different immunological responses^{20–22}. Specifically, *IL17A* polymorphisms, located in the promoter region of the gene, have been associated with plasma *IL-17A* levels in cell cultures²⁰ and in healthy infants²³. Several studies have found associations between the *IL17A* gene polymorphisms with infectious diseases, such as, cutaneous leishmaniasis²⁴, brucellosis²⁵, and tuberculosis²⁶.

A previous study performed, by our group, in a Colombian cohort, observed nominal significant associations between variants of *IL17A* gene with the susceptibility to *T. cruzi* infection and with the development of chronic cardiomyopathy²⁷. An additional study conducted in the South and Southeast regions of Brazil also found an association with *IL17A* and *IL17F* variants and the susceptibility to the development of chronic Chagas cardiomyopathy²⁸.

Given the limited information about the role of *IL17A* gene variants in Chagas disease, this study aimed to analyse the association of three *IL17A* genetic variants with the predisposition to *T. cruzi* infection, the development of chronic cardiomyopathy and chronic Chagas cardiomyopathy, in different Latin American populations.

Results

A total of 2,967 patients were included in the study. The demographic characteristics of the studied cohorts are reported in Table 1.

The three single nucleotide polymorphisms (SNPs) of *IL17A* gene: rs4711998, rs8193036 and rs2275913, selected for this study, were in Hardy–Weinberg equilibrium in all the analysed cohorts ($P > 0.01$). The genotyping success rate was over 95% and the allele frequencies in all cases were similar to those described for the Americans sub-populations of the 1000 Genomes Project phase III (<http://www.1000genomes.org>)²⁹ (Table S1).

***T. cruzi* infection susceptibility.** The allelic and genotypic frequencies of seronegative and seropositive individuals from the Colombian cohort were compared in Tables S3–1. The minor allele frequency (MAF), in rs8193036*C was higher in seronegative than in seropositive individuals, being nominally significant after the adjustment by sex and age [$P = 0.043$, odds ratio (OR) = 0.83, 95% confidence interval (CI) = 0.70–0.99]. No associations between the three *IL17A* genetic variants and susceptibility to *T. cruzi* infection were found after performing logistic regression adjusted by sex and age in the Argentinian cohort (Tables S3–2). In contrast, interestingly, the SNP *IL17A* rs2275913*A, that was studied in a Brazilian cohort, was found statistically significant for the risk to *T. cruzi* infection²⁸. Furthermore, a meta-analysis combining each individual cohort (Colombian, Argentinian and Brazilian) was performed (Table 2). The *IL17A* rs2275913*A allele effect was consistent in the three cohorts and the association improved after the meta-analysis, showing statistically significant results ($P = 0.016$, OR = 1.21, 95% CI = 1.06–1.41, under a fixed-effects meta-analysis) after Bonferroni correction. No association was observed for the *IL17A* rs4711998 and rs8193036.

Chronic chagas cardiomyopathy susceptibility. To understand the genetic basis of chronic Chagas cardiomyopathy, we compared CCC and asymptomatic patients. The allelic frequencies of *IL17A* variants in

SNP	Colombian cohort		Argentinian cohort		Bolivian cohort		Brazilian cohort		Meta-analysis	
	OR (L95-U95)	P	OR (L95-U95)	P	OR (L95-U95)	P	OR (L95-U95)	P	OR (L95-U95)	P
rs4711998*A	0.86 (0.67–1.11)	0.259	1.08 (0.69–1.68)	0.751	0.96 (0.65–1.41)	0.831	—	—	0.92 (0.76–1.11)	0.396
rs8193036*C	0.92 (0.72–1.18)	0.526	0.74 (0.49–1.29)	0.164	1.18 (0.85–1.62)	0.319	—	—	0.95 (0.80–1.14)	0.616
rs2275913*A	0.8 (0.62–1.02)	0.081	0.72 (0.43–1.21)	0.217	1.14 (0.75–1.71)	0.543	1.21 (0.74–1.99)	0.463	0.89 (0.74–1.07)	0.232

Table 3. Meta-analysis of *IL17A* variants, Latin American cohorts for chronic Chagas cardiomyopathy susceptibility (CCC vs. asymptomatic patients). Total number of individuals: rs4711998 and rs8193036: CCC, n = 858 and asymptomatic, n = 981; rs2275913: CCC, n = 1070 and asymptomatic, n = 1029. OR: odds ratios, L95-U95: confidence intervals of 95% L: lower limit; U: upper limit.

SNP	Colombian cohort		Argentinian cohort		Brazilian cohort		Meta-analysis	
	OR (L95-U95)	P	OR (L95-U95)	P	OR (L95-U95)	P	OR (L95-U95)	P
rs4711998*A	0.93 (0.75–1.16)	0.541	1.47 (0.92–2.37)	0.109	—	—	1.02 (0.82–1.23)	0.927
rs8193036*C	0.84 (0.67–1.05)	0.133	1.21 (0.78–1.88)	0.389	—	—	0.91 (0.74–1.10)	0.323
rs2275913*A	1.14 (0.90–1.44)	0.298	0.99 (0.60–1.61)	0.955	1.52 (1.08–2.15)	0.021	1.20 (1.01–1.45)	0.040

Table 4. Meta-analysis of *IL17A* variants, Latin American cohorts for chronic cardiomyopathy susceptibility (CCC vs. seronegative individuals). Total number of individuals: rs4711998 and rs8193036: CCC, n = 758 and seronegative, n = 718; rs2275913: CCC, n = 970 and seronegative, n = 868. OR: odds ratios, L95-U95: confidence intervals of 95% L: lower limit; U: upper limit.

patients from the Colombian, Argentinian and Bolivian cohorts were not statistically significant after the logistic regression adjusted by sex and age (Tables S4–1–3), consistent with previous findings in the Brazilian cohort²⁸. Moreover, no significant associations were detected for the available SNPs when the meta-analysis was performed combining these cohorts (Table 3).

Finally, in order to evaluate the possible association between *IL17A* genetic variants and chronic cardiomyopathy we compared CCC patients and seronegative individuals, as previously performed^{27,28}. In the Colombian and Argentinian cohort (Tables S5–1 and 2) and no associations were found after applying logistic regression adjusted by sex and age. In contrast, a previous study, in the Brazilian cohort the *IL17A* rs2275913*A allele was nominally significant²⁸. As can be observed in Table 4 the *IL17A* rs2275913 allele effect was consistent in the Colombian, Argentinian and Brazilian cohorts, and the association with chronic cardiomyopathy susceptibility improved after the meta-analysis showing nominally statistical differences ($P = 0.040$, OR = 1.20, 95% CI = 1.01–1.45, under a fixed-effects meta-analysis). These results suggest that rs2275913*A allele was associated with the risk of cardiomyopathy in the analysed population.

In silico functional characterization of *IL17A* gene variants. Since the *IL17A* rs2275913 showed a statistical association with the risk to *T. cruzi* infection and the development of chronic cardiomyopathy, we perform an *in silico* functional analysis of this SNP and the ones in high LD ($R^2 \geq 0.8$) on peripheral mononuclear blood in American population from the 1000 Genomes Project (Table 5). The annotation indicates that these SNPs map in enhancer regions and marks of histone modifications (H3K4me1, H3K4me3, H3K27ac and chromatin marks), potentially modulating gene expression.

Discussion

Association studies offer a potentially powerful approach to identify genetic variations that are involved in the immunopathogenesis of Chagas disease^{16–19}. However, individual genetic association studies frequently have limitations and the results may be specific to the population of the study. The meta-analysis approach has been proposed to resolve these limitations, to increase the power of statistical analyses^{30,31} and to reach to more conclusive results in order to improve our understanding of the genetic basis underlying Chagas disease. In this study, three *IL17A* genetic variants were analysed in four Latin American populations, and our results evidenced the implication of rs2275913 associated with the risk to *T. cruzi* infection and the development of chronic cardiomyopathy, in Colombian, Argentinian and Brazilian population.

In the early stages of the infection, the IL-17A is a crucial cytokine secreted by a wide range cell types such as Th17, B cells, innate lymphoid cells, CD4+, CD8+, gamma-delta T and invariant NKT^{10–13,32}. The rs2275913, which was associated with the risk to *T. cruzi* infection in the Latin American population studied, is a functional polymorphism that modifies the binding of the transcriptional nuclear factor of activated T cells (NFAT) in the IL-17A promoter. Moreover, as observed in the *in silico* analysis, the associated variant is located in promoter histone marks, potentially modulating gene expression. In addition, it has been demonstrated that the substitution of the G by an A allele in the *IL17A* rs2275913 gene promoter was significantly associated with autoimmune diseases and cancer^{33–36}. However, controversial results have been reported regarding the levels of IL-17A in serum, where the A allele was associated with a higher^{20,36,37}, lower^{38,39} or no significant⁴⁰ levels of transcription and synthesis of the protein. In this work, we could hypothesized that the individuals who carry the A allele in the *IL17A* rs2275913 would be more susceptibility to the *T. cruzi* infection, probably due to a variation in the gene

Position ^a	SNPs	R ²	Functionality	MAF (AMR)	eQTL	Chromatin states ^b	Chromatin states ^c	H3K4me1	H3K4me3	H3K27ac
chr6:52051033	rs2275913	1	Intergenic variant	25%	—	Flank	Promoter	Enhancer	Promoter	Enhancer
chr6:52087034	rs11966760	0.82	Intergenic variant	24%	PAQR8	Enhancer	Promoter	Enhancer	Promoter	Enhancer
chr6:52056386	rs16882180	0.8	Intergenic variant	25%	PAQR8	—	—	Enhancer	Promoter	—

Table 5. Functional annotation. Regulatory chromatin states and histone modifications for *IL17A* rs2275913 and SNPs in high LD ($R^2 \geq 0.8$). Functional annotation from mononuclear peripheral blood specifically primary T helper 17 cells. ^aAccording to National Center for Biotechnology Genome Reference Consortium NCBI build GRCh37. ^bCore 15-state model. ^cChromatin states: 25-state model using 12 imputed marks. H3K4me1: Histone H3 lysine 4 mono-methylation, H3K4me3: Histone H3 lysine 4 tri-methylation, H3K27ac: Histone H3 lysine 27 acetylation. MAF: Minor Allele Frequency. AMR: American.

expression and therefore lower IL-17A production, which would impede a rapid proinflammatory activation of chemokines and cytokines for the resolution of *T. cruzi* infection^{12,13}. However, further studies are required to understand the complexity of *IL17A* rs2275913 polymorphism functional effect.

Several studies showed that IL-17A has an important immunomodulatory role in the chronic phase of the disease^{8,14,15,41}. IL-17 expression by Th17 cells and B cells were found in patients with cardiac involvement more frequently, compared to asymptomatic patients, correlating with worse cardiac function¹⁴; IL-17 exacerbated produce a proinflammatory environment in Chagas severe heart disease^{42,43}. However controversially, others groups suggested a protective role of IL-17 and Th17 in the chronic cardiac form^{44,45}. Regarding *IL17A* genetic variants, in our study, no significant association was detected when CCC and asymptomatic patients from Colombia, Argentina, Bolivia and Brazil were compared. This lack of association could be a consequence of an insufficient statistical power (Table S1) or genetic heterogeneity among the studied cohorts. The lack of replication may occur if the studied polymorphism is not the causal variant but is rather in LD with it. LD patterns depend on the genetic background of the founder population and population history, always challenging in Latin American population due to their genetic diversity and recent admixture^{46–48}.

Interestingly, at the present time IL-17A have become a relevant drug target in various forms of autoimmune and inflammatory diseases, mainly as negative modulators of the secreted protein^{13,49}. Two antibodies are currently in Phase IV of drug development for the treatment of immune system diseases, namely, Secukinumab and Ixekizumab (Anatomical Therapeutic Chemical [ATC] code L04AC10 and L04AC13, respectively). Given the role of IL-17A as a key cytokine in the pathogenesis of Chagas disease, the opportunities for drug repurposing becomes very important for this neglected disease, as there are only two treatments available: Benznidazole and Nifurtimox, with high rates of adverse effects and treatment withdrawal^{50,51}.

In conclusion, in this work, we found an association of *IL17A* rs2275913 with Chagas disease in a large cohort composed of different Latin American countries, validating previous findings^{27,28}. Finally, further studies on this gene accounting for functional analyses and heterogeneity among populations, would be necessary for the complete understanding of *IL17A* polymorphisms in Chagas disease.

Materials and Methods

Study design and patient population. A candidate-gene case-control study was performed in Colombian, Argentinian and Bolivian cohorts in order to replicate previous findings^{27,28}. In addition, to improve the statistical power of the study a meta-analysis was performed combining the results from all the available cohorts.

A total of 2,967 individuals from Latin American countries (Argentina, Bolivia Colombia and Brazil) were studied. In all cohorts, patients were classified as seropositive for *T. cruzi* antigens ($n = 2,099$) and seronegative ($n = 868$) on the basis of results of at least 2 of 3 independent tests. Among seropositive individuals, based on electrocardiographic, echocardiographic, chest X-ray and clinical findings, patients were classified as chronic Chagas cardiomyopathy (CCC, $n = 1,070$) and asymptomatic (ASY, $n = 1,029$).

Colombian cohort. A total of 406 Colombian individuals from the same population as the study by Leon Rodriguez *et al.*²⁷ were recruited by the health care team from the Industrial University of Santander and Cardiovascular Foundation from Colombia. In order to increase the sample size, these individuals were included with the previously published Colombian cohort, making a total of 1,577 individuals. From this, 937 were classified as seropositive for *T. cruzi* antigens and 640 were classified as seronegative (according to the serological tests: recombinant antigen ELISA and commercial indirect hemagglutination test). Subsequently, and after a clinical evaluation, an electrocardiogram (ECG) and an echocardiogram (Echo) were recorded to detect any conduction and/or structural alteration in seropositive patients. Based on complementary tests and clinical findings, seropositive patients were classified as CCC = 576 and ASY = 361. The mean age of participants was 45.55 ± 17.19 years for seronegative individuals, CCC = 61.44 ± 12.82 and ASY = 51.90 ± 14.18 . The sex distribution was 58% female and 42% male⁵².

Argentinian cohort. A total of 350 Argentinian individuals from an endemic region for Chagas disease (Cordoba province) were included in this study. The study subjects were recruited from the National Hospital of Clinics and Sucre Clinic, Cordoba city. The population in this region of Argentina is a homogeneous mixture, with no specific concentration of any ethnicity. All participants underwent a serological diagnosis for *T. cruzi* infection

by means of the enzyme-linked immunosorbent assay (ELISA) that uses recombinant antigen and a commercial indirect hemagglutination test. According to the results of these tests, 272 individuals were classified as seropositive for *T. cruzi* antigens and 78 were classified as seronegative. Based on the results of clinical findings, ECG and Echo, seropositive patients were classified as CCC, $n = 182$ and ASY, $n = 90$. The mean age of participants was 53.82 ± 16.53 years for seronegative individuals, 49.30 ± 13.65 for asymptomatic individuals and 60.14 ± 10.16 for chronic Chagas cardiomyopathy patients. The sex distribution was 71% female and 29% male⁵².

Bolivian cohort. A total of 630 Bolivian individuals residents in Barcelona, Spain were recruited from the Infectious Diseases Department of the Vall d'Hebron University Hospital. In this cohort only seropositive patients were classified as CCC, $n = 100$ and ASY, $n = 530$ based on the results of clinical findings, ECG and Echo. The sex distribution was 69% female and 31% male. The mean age of the participants was ASY: 46.93 ± 9.49 CCC: 50.71 ± 9.41 ⁵².

Brazilian cohort. Data from 410 Brazilian individuals drawn from Reis *et al.* 2017, originally from South and Southeast regions of Brazil were included in the meta-analysis²⁸. From this, 260 were classified as seropositive for *T. cruzi* antigens and 150 were classified as seronegative. Based on complementary tests and clinical findings, seropositive patients were classified as CCC = 212 and ASY = 48.

Ethics statement. The study was accepted by the Ethics Committees from the Industrial University of Santander and Cardiovascular Foundation, Colombia [Act No. 15/2005]; the Vall d'Hebron University Hospital, Barcelona, Spain and the National Hospital of Clinics [PR (AMI) 297/2016], National University of Cordoba, Argentina [CIEIS HNC 118/2012 and 2/16/2017]. Written informed consent was obtained from all subjects prior to participation. The research protocols followed the principles of the Declaration of Helsinki and informed consent was obtained from all individual participants included in the study.

Selected polymorphisms and genotyping. Three SNPs of *IL17A* gene (rs4711998, rs8193036 and rs2275913) were selected for this study. These SNPs were previously assessed in Chagas disease in a Colombian cohort and in a Brazilian cohort²⁸. These SNPs are independent intergenic variants mapping to the promoter region of *IL17A*⁵³ (linkage disequilibrium [LD], $r^2 < 0.2$ estimated using LDlink website tool [<https://ldlink.nci.nih.gov/?tab=ldmatrix>]).

Genomic DNA from blood samples was isolated following standard procedures and the genotyping was performed using TaqMan assays (Applied Biosystems, Foster City, California, USA) on a real-time PCR system (7900HT Fast Real-Time PCR System), SNPs were determined by TaqMan 5' allelic discrimination assay method performed by Applied Biosystems⁵².

Statistical analysis. For the candidate gene study, the statistical analyses were performed with the software Plink V1.9 (<https://www.cog-genomics.org/plink2>)⁵⁴. Deviance from Hardy-Weinberg equilibrium was determined at the 1% significance level in all groups of individuals. Individuals that did not achieved an SNP completion rate of 95% were filtered out. To test for possible allelic association, logistic regression model and Fisher's exact test were assessed in seronegative vs. seropositive individuals and asymptomatic vs. chronic Chagas cardiomyopathy individuals, using age and sex as covariates; and odds ratios (OR) and 95% confidence intervals (CI) were calculated. P-values lower than 0.05 were considered as statistically significant.

To assess the consistency of effects across the cohorts, a meta-analysis was performed with METASOFT (<http://genetics.cs.ucla.edu/meta/>) based on inverse-variance-weighted effect size. Heterogeneity across studies was assessed using the Cochran's Q statistic (Q test $P < 0.05$) and I^2 heterogeneity index⁵⁵. A fixed-effects model was applied for those SNPs without evidence of heterogeneity (Cochran's Q test $P > 0.05$), and a random-effects model was applied for SNPs displaying heterogeneity of effects between studies (Cochran's Q test $P \leq 0.05$). The significance threshold for the meta-analyses was estimated based on the Bonferroni correction ($0.05/3 = 0.017$)⁵⁶.

The statistical power of the studies was estimated with the Power Calculator for Genetic Studies 2006 (CaTS) software (Tables S1 and S2) (<http://www.sph.umich.edu/csg/abecasis/CaTS/>)⁵⁷.

In silico functional characterization of *IL17A* gene variants. Evaluation of functionality of the statistically significant associated SNP with Chagas disease, was performed with the online software HaploReg v4.1⁵⁸. (<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>) based on empirical data from the ENCODE project (<http://www.genome.gov/encode/>). Specifically, we focused our attention on experiments performed on blood in the American population. Moreover, updated information related to expression Quantitative Trait Loci (eQTL) were inspected for *IL17A* rs2275913 and for SNPs in high LD ($R^2 \geq 0.8$) (Table 5).

Data availability

All relevant data are within the paper and its Supporting Information files.

Received: 18 November 2019; Accepted: 5 March 2020;

Published online: 19 March 2020

References

1. WHO. Fourth WHO report on neglected tropical diseases. (Integrating neglected tropical diseases into global health and development, 2017).
2. Coura, J. R. & Dias, J. C. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. *Mem. Inst. Oswaldo Cruz* **104**(Suppl 1), 31–40 (2009).
3. Coura, J. R. Chagas disease: what is known and what is needed—a background article. *Mem. Inst. Oswaldo Cruz* **102**(Suppl 1), 113–22 (2007).

4. Gupta, S. *et al.* TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster Immunization. *Front. Immunol.* **10**, 1456 (2019).
5. Pérez-Molina, J. A. & Molina, I. Chagas disease. *Lancet* **391**, 82–94 (2018).
6. Martínez, F. *et al.* Chagas Disease and Heart Failure: An Expanding Issue Worldwide. *Eur. Cardiol.* **14**(2), 82–88 (2019).
7. Umezawa, E. S. *et al.* Chagas' disease. *Lancet* **359**, 627 (2002).
8. da Matta Guedes, P. M. *et al.* IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. *PLoS Negl. Trop. Dis.* **4**, e604 (2010).
9. Cai, C. W., Blase, J. R., Zhang, X., Eickhoff, C. S. & Hoft, D. F. Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruzi. *PLoS Pathog.* **12**, e1005902 (2016).
10. Bermejo, D. A. *et al.* Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors ROR γ and Ahr that leads to IL-17 production by activated B cells. *Nat. Immunol.* **14**, 514–22 (2013).
11. Gorosito Serran, M. *et al.* Unconventional Pro-inflammatory CD4(+) T Cell Response in B Cell-Deficient Mice Infected with Trypanosoma cruzi. *Front. Immunol.* **8**, 1548 (2017).
12. Miyazaki, Y. *et al.* IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection. *J. Immunol.* **185**, 1150–7 (2010).
13. Chen, K. & Kolls, J. K. Interleukin-17A (IL17A). *Gene* **614**, 8–14 (2017).
14. Almeida, M. S. *et al.* Alternative Th17 and CD4(+) CD25(+) FoxP3(+) cell frequencies increase and correlate with worse cardiac function in Chagas cardiomyopathy. *Scand. J. Immunol.* **87**, e12650 (2018).
15. Bestetti, R. B. *et al.* Determination of the Th1, Th2, Th17, and Treg cytokine profile in patients with chronic Chagas heart disease and systemic arterial hypertension. *Heart Vessel.* **34**, 123–133 (2019).
16. Cunha-Neto, E. & Chevillard, C. Chagas disease cardiomyopathy: immunopathology and genetics. *Mediators Inflamm.* **2014**, 683230 (2014).
17. Ortega Zamora, Y. *et al.* Chagas disease immunogenetics: elusive markers of disease progression. *Expert Rev Cardiovasc Ther.* **1**–10 (2017).
18. Chevillard, C. *et al.* Disease Tolerance and Pathogen Resistance Genes May Underlie Trypanosoma cruzi Persistence and Differential Progression to Chagas Disease Cardiomyopathy. *Front. Immunol.* **9**, 2791 (2018).
19. Acosta-Herrera, M., Strauss, M., Casares-Marfil, D. & Martin, J. & Chagas Genetics, C. N. Genomic medicine in Chagas disease. *Acta Trop.* **197**, 105062 (2019).
20. Espinoza, J. L. *et al.* A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. *PLoS One* **6**, e26229 (2011).
21. Keshavarz, M. *et al.* Association of polymorphisms in inflammatory cytokines encoding genes with severe cases of influenza A/H1N1 and B in an Iranian population. *Virology* **16**, 79 (2019).
22. Batista, A. M. *et al.* Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas' Heart Disease: Antagonistic Participation of CCR1(+) and CCR5(+) Cells in Chronic Chagasic Cardiomyopathy. *Front. Immunol.* **9**, 615 (2018).
23. Vuononvirta, J., Peltola, V., Ilonen, J., Mertsola, J. & He, Q. The Gene Polymorphism of IL-17 G-152A is Associated with Increased Colonization of Streptococcus pneumoniae in Young Finnish Children. *Pediatr. Infect. Dis. J.* **34**, 928–32 (2015).
24. Gonçalves de Albuquerque, S. D. C. *et al.* Study of association of the rs2275913 IL-17A single nucleotide polymorphism and susceptibility to cutaneous leishmaniasis caused by Leishmania braziliensis. *Cytokine* **123**, 154784 (2019).
25. Keramat, F. *et al.* Association of interleukin-17 gene polymorphisms and susceptibility to brucellosis in Hamadan, western Iran. *Microbiol. Immunol.* **63**, 139–146 (2019).
26. Eskandari-Nasab, E. *et al.* Interleukin-17 A and F gene polymorphisms affect the risk of tuberculosis: An updated meta-analysis. *Indian J. Tuberc.* **65**, 200–207 (2018).
27. Leon Rodriguez, D. A., Echeverria, L. E., Gonzalez, C. I. & Martin, J. Investigation of the role of IL17A gene variants in Chagas disease. *Genes Immun.* **16**, 536–40 (2015).
28. Reis, P. G. *et al.* Genetic Polymorphisms of IL17 and Chagas Disease in the South and Southeast of Brazil. *J. Immunol. Res.* **2017**, 1017621 (2017).
29. Genomes Project, C. *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nat.* **491**, 56–65 (2012).
30. Zhang, H. *et al.* A Powerful Procedure for Pathway-Based Meta-analysis Using Summary Statistics Identifies 43 Pathways Associated with Type II Diabetes in European Populations. *PLoS Genet.* **12**, e1006122 (2016).
31. Lona-Durazo, F. *et al.* Meta-analysis of GWA studies provides new insights on the genetic architecture of skin pigmentation in recently admixed populations. *BMC Genet.* **20**, 59 (2019).
32. Taylor, P. R. *et al.* Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR γ and dectin-2. *Nat. Immunol.* **15**, 143–51 (2014).
33. Nordang, G. B. *et al.* Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. *Rheumatol.* **48**, 367–70 (2009).
34. Duan, Y., Shi, J. N., Pan, C., Chen, H. L. & Zhang, S. Z. Association between the interleukin-17A -197G>A (rs2275913) polymorphism and risk of digestive cancer. *Asian Pac. J. Cancer Prev.* **15**, 9295–300 (2014).
35. Hayashi, R. *et al.* Influence of IL17A polymorphisms (rs2275913 and rs3748067) on the susceptibility to ulcerative colitis. *Clin. Exp. Med.* **13**, 239–44 (2013).
36. Pasha, H. F., Tantawy, E. A. & Youssef, M. A. Osteopontin and interleukin-17A genes polymorphisms in Egyptian systemic lupus erythematosus patients: A relation to disease activity and severity. *Gene* **702**, 107–113 (2019).
37. Rolandelli, A. *et al.* The IL-17A rs2275913 single nucleotide polymorphism is associated with protection to tuberculosis but related to higher disease severity in Argentina. *Sci. Rep.* **7**, 40666 (2017).
38. Huang, H. T. *et al.* The association of IL-17A polymorphisms with IL-17A serum levels and risk of ischemic stroke. *Oncotarget* **8**, 103499–103508 (2017).
39. Li, N. *et al.* IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. *Mol. Carcinog.* **53**, 447–57 (2014).
40. Mohammadipour, K., Mansouri, R., Salmanpour, R., Haghshenas, M. R. & Erfani, N. Investigation of Interleukin-17 Gene Polymorphisms and Serum Levels in Patients with Basal Cell Carcinoma of the Skin. *Iran. J. Immunol.* **16**, 53–61 (2019).
41. Vesely, M. C. A., Rodriguez, C., Gruppi, A. & Rodriguez, E. V. A. Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans. *Biochim. Biophys. Acta Mol. Basis Dis.* **24**, 165706 (2020).
42. Nogueira, L. G. *et al.* Myocardial gene expression of T-bet, GATA-3, Ror- γ t, FoxP3, and hallmark cytokines in chronic Chagas disease cardiomyopathy: an essentially unopposed T-Type response. *Mediators Inflamm* 914326 (2014).
43. Sousa, G. R. *et al.* Plasma cytokine expression is associated with cardiac morbidity in chagas disease. *PLoS One* **9**, e87082 (2014).
44. Guedes, P. M. M. *et al.* Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. *PLoS Negl. Trop. Dis.* **6**, e1630 (2012).
45. Magalhaes, L. M. *et al.* High interleukin 17 expression is correlated with better cardiac function in human Chagas disease. *J. Infect. Dis.* **207**(4), 661–5 (2013).
46. Bryc, K. *et al.* Colloquium paper: genome-wide patterns of population structure and admixture among Hispanic/Latino populations. *Proc. Natl Acad. Sci. USA* **107**(Suppl 2), 8954–61 (2010).

47. Hirschhorn, J. N., Lohmueller, K., Byrne, E. & Hirschhorn, K. A comprehensive review of genetic association studies. *Genet. Med.* **4**, 45–61 (2002).
48. Norris, E. T. *et al.* Genetic ancestry, admixture and health determinants in Latin America. *BMC Genomics* **19**, 861 (2018).
49. Tavakolpour, S., Darvishi, M. & Ghasemiadl, M. Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases. *Clin. Genet.* **93**, 481–497 (2018).
50. Rojo, G. *et al.* Toxic and therapeutic effects of Nifurtimox and Benznidazol on *Trypanosoma cruzi* *ex vivo* infection of human placental chorionic villi explants. *Acta Trop.* **132**, 112–8 (2014).
51. Salvador, F. *et al.* Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. *Clin. Infect. Dis.* **61**(Suppl 11), 1688–94 (2015).
52. Strauss, M. *et al.* Association of IL18 genetic polymorphisms with Chagas disease in Latin American populations. *PLoS Negl. Trop. Dis.* **13**, e0007859 (2019).
53. Wang, J. Y. *et al.* The polymorphisms of interleukin 17A (IL17A) gene and its association with pediatric asthma in Taiwanese population. *Allergy* **64**, 1056–60 (2009).
54. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
55. Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. *Am. J. Hum. Genet.* **88**, 586–98 (2011).
56. Armstrong, R. A. When to use the Bonferroni correction. *Ophthalmic Physiol. Opt.* **34**, 502–8 (2014).
57. Skol, A. D., Scott, L. J., Abecasis, G. R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat. Genet.* **38**, 209–13 (2006).
58. Ward, L. D. & Kellis, M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res.* **44**, D877–81 (2016).

Acknowledgements

We thank all the patients who participated in this study and the Medical team from the different Latin American countries and Spain. This research was supported by grants from Ministerio de Ciencia y Tecnología de Córdoba (GRFT 2017), Secretaría de Ciencia y Tecnología, Universidad Nacional de Córdoba, Argentina and Red Iberoamericana de Medicina Genómica en enfermedad de Chagas – CYTED (<http://www.cyteted.org>).

Author contributions

M.S., M.S.L.P., I.M., C.I.G., J.M., M.A.H. and C.G.C.N. defined the experimental design and conceptualization. M.S., M.P.V., D.C.M., P.B.N. and M.A.H. performed the allelic discrimination, data curation, formal analysis and functional annotation. J.M. and M.A.H. supervised the procedures. M.S., M.P.V. and D.C.M. drafted the first version of the manuscript under the supervision of M.A.H. and J.M. All the authors reviewed and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-61965-5>.

Correspondence and requests for materials should be addressed to M.S., J.M. or M.A.-H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

Consortia

Chagas Genetics CYTED Network

Patricia A. Paglini¹, Alejandro G. Schijman⁵, Carlos Robello⁶, Luis E. Echeverría⁷, Gilberto Vargas-Alarcón⁸, José E. Calzada⁹, Mercedes Fernández-Mestre¹⁰, Manuel Fresno¹¹ & Maria Jesus Pinazo¹²

⁵Laboratorio de Biología Molecular de la Enfermedad de Chagas, INGEBI-CONICET, Buenos Aires, Argentina.

⁶Laboratorio de Interacción Hospedero-Patógeno -UBM, Instituto Pasteur de Montevideo, Montevideo, Uruguay.

⁷Clínica de insuficiencia cardíaca y trasplante de corazón, Fundación Cardiovascular de Colombia, Floridablanca, Colombia. ⁸Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, México, México.

⁹Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES), Panamá, Panamá. ¹⁰Laboratorio de Fisiopatología, Centro de Medicina Experimental, Instituto Venezolano de Investigaciones Científicas, Caracas, 21827, Venezuela. ¹¹Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Madrid, España. ¹²ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, España.